Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Retinitis Pigmentosa
NCT03999021Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jun 2019
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetylcysteine in retinitis pigmentosa (RP), sponsored by Johns Hopkins University. Primary endpoints: Blood Pressure up to 2 years, Tolerability of N-Acetylcysteine as assessed by drug-related symptoms up to 2 years and 2 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT03999021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999021.